CTLA4 and Telangiectasia: HLH is a fatal systemic inflammatory syndrome reported as a rare irAE in patients receiving nivolumab, ipilimumab, and/or pembrolizumab.Neuromuscular junction dysfunction (myasthenia gravis) was over-reported in patients treated with anti-PD-1/PD-L1 compared with anti-CTLA-4.Currently, 5 cases of acquired hemophilia A related to ICIs have been reported, including: ipilimumab, nivolumab, and atezolizumab.Camrelizumab: RCCEP, mainly manifesting as facial telangiectasia and the appearance of red blood streaks.Pembrolizumab: autoimmune polyendocrine syndrome.